Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Human Microbiome Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 10-06-2019
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
Disease
Obesity
Diabetes
Autoimmune Disorder
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Other Diseases
Product
Probiotics
Prebiotics
Symboitics
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
isease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Human Insulin Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The global human insulin market is expected to register a CAGR of 4.93% during the forecast period of 2019 – 2024 and is estimated to reach USD 25.7 billion by 2019.
Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world.
Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.
Scope of the Report
The market is segmented by product type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins) and geography.
Key Market Trends
Growing Obesity and Diabetes Prevalence of Type 2, Especially in Developing Countries
The exact cause of Type 1 diabetes is unknown, but Type 2 diabetes is caused by lifestyle changes happening daily. The prevalence rate of Type 2 diabetes has quadrupled, when compared to 40 years ago. Although oral drugs are considered as a standard care treatment for Type 2 patients, there has been a rise in the need for using insulin, along with the conventional medication, in order to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter into the biosimilar market.
The prevalence of Type 2 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and the primary risk factor for T2DM. Diabetes ranks among the fast-growing chronic diseases in the United States.
India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits. Significant urbanization has enabled physical inactivity and diabetes is a major health concern.
The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients’ use, curbing out maximum side effects and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.
North America Dominates the Market
North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region, because of a sedentary lifestyle and launch of new drugs in the region.
The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity and rising awareness regarding diabetes care in the region.
Competitive Landscape
The global human insulin market is highly fragmented with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers.
Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine).
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.1.1.1 Lantus
5.1.1.2 Levemir
5.1.1.3 Toujeo
5.1.1.4 Tresiba
5.1.1.5 Basaglar
5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
5.1.2.1 NovoRapid/Novolog
5.1.2.2 Humalog
5.1.2.3 Apidra
5.1.3 Traditional Human Insulins (Value and Volume, 2012-2024)
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Combination Insulins (Value and Volume, 2012-2024)
5.1.4.1 NovoMix
5.1.4.2 Ryzodeg
5.1.4.3 Xultophy
5.1.5 Biosimilar Insulins (Value and Volume, 2012-2024)
5.1.5.1 Insulin Glargine Biosimilars
5.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 Basal or Long-acting Insulins
5.2.1.1.2 Bolus or Fast-acting Insulins
5.2.1.1.3 Traditional Human Insulins
5.2.1.1.4 Combination Insulins
5.2.1.1.5 Biosimilar Insulins
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 Basal or Long-acting Insulins
5.2.1.2.2 Bolus or Fast-acting Insulins
5.2.1.2.3 Traditional Human Insulins
5.2.1.2.4 Combination Insulins
5.2.1.2.5 Biosimilar Insulins
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 Basal or Long-acting Insulins
5.2.1.3.2 Bolus or Fast-acting Insulins
5.2.1.3.3 Traditional Human Insulins
5.2.1.3.4 Combination Insulins
5.2.1.3.5 Biosimilar Insulins
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 Basal or Long-acting Insulins
5.2.2.1.2 Bolus or Fast-acting Insulins
5.2.2.1.3 Traditional Human Insulins
5.2.2.1.4 Combination Insulins
5.2.2.1.5 Biosimilar Insulins
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 Basal or Long-acting Insulins
5.2.2.2.2 Bolus or Fast-acting Insulins
5.2.2.2.3 Traditional Human Insulins
5.2.2.2.4 Combination Insulins
5.2.2.2.5 Biosimilar Insulins
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 Basal or Long-acting Insulins
5.2.2.3.2 Bolus or Fast-acting Insulins
5.2.2.3.3 Traditional Human Insulins
5.2.2.3.4 Combination Insulins
5.2.2.3.5 Biosimilar Insulins
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 Basal or Long-acting Insulins
5.2.2.4.2 Bolus or Fast-acting Insulins
5.2.2.4.3 Traditional Human Insulins
5.2.2.4.4 Combination Insulins
5.2.2.4.5 Biosimilar Insulins
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 Basal or Long-acting Insulins
5.2.2.5.2 Bolus or Fast-acting Insulins
5.2.2.5.3 Traditional Human Insulins
5.2.2.5.4 Combination Insulins
5.2.2.5.5 Biosimilar Insulins
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 Basal or Long-acting Insulins
5.2.2.6.2 Bolus or Fast-acting Insulins
5.2.2.6.3 Traditional Human Insulins
5.2.2.6.4 Combination Insulins
5.2.2.6.5 Biosimilar Insulins
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 Basal or Long-acting Insulins
5.2.2.7.2 Bolus or Fast-acting Insulins
5.2.2.7.3 Traditional Human Insulins
5.2.2.7.4 Combination Insulins
5.2.2.7.5 Biosimilar Insulins
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 Basal or Long-acting Insulins
5.2.3.1.2 Bolus or Fast-acting Insulins
5.2.3.1.3 Traditional Human Insulins
5.2.3.1.4 Combination Insulins
5.2.3.1.5 Biosimilar Insulins
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 Basal or Long-acting Insulins
5.2.3.2.2 Bolus or Fast-acting Insulins
5.2.3.2.3 Traditional Human Insulins
5.2.3.2.4 Combination Insulins
5.2.3.2.5 Biosimilar Insulins
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 Basal or Long-acting Insulins
5.2.3.3.2 Bolus or Fast-acting Insulins
5.2.3.3.3 Traditional Human Insulins
5.2.3.3.4 Combination Insulins
5.2.3.3.5 Biosimilar Insulins
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 Basal or Long-acting Insulins
5.2.4.1.2 Bolus or Fast-acting Insulins
5.2.4.1.3 Traditional Human Insulins
5.2.4.1.4 Combination Insulins
5.2.4.1.5 Biosimilar Insulins
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 Basal or Long-acting Insulins
5.2.4.2.2 Bolus or Fast-acting Insulins
5.2.4.2.3 Traditional Human Insulins
5.2.4.2.4 Combination Insulins
5.2.4.2.5 Biosimilar Insulins
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 Basal or Long-acting Insulins
5.2.4.3.2 Bolus or Fast-acting Insulins
5.2.4.3.3 Traditional Human Insulins
5.2.4.3.4 Combination Insulins
5.2.4.3.5 Biosimilar Insulins
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 Basal or Long-acting Insulins
5.2.4.4.2 Bolus or Fast-acting Insulins
5.2.4.4.3 Traditional Human Insulins
5.2.4.4.4 Combination Insulins
5.2.4.4.5 Biosimilar Insulins
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 Basal or Long-acting Insulins
5.2.4.5.2 Bolus or Fast-acting Insulins
5.2.4.5.3 Traditional Human Insulins
5.2.4.5.4 Combination Insulins
5.2.4.5.5 Biosimilar Insulins
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 Basal or Long-acting Insulins
5.2.4.6.2 Bolus or Fast-acting Insulins
5.2.4.6.3 Traditional Human Insulins
5.2.4.6.4 Combination Insulins
5.2.4.6.5 Biosimilar Insulins
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 Basal or Long-acting Insulins
5.2.4.7.2 Bolus or Fast-acting Insulins
5.2.4.7.3 Traditional Human Insulins
5.2.4.7.4 Combination Insulins
5.2.4.7.5 Biosimilar Insulins
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 Basal or Long-acting Insulins
5.2.4.8.2 Bolus or Fast-acting Insulins
5.2.4.8.3 Traditional Human Insulins
5.2.4.8.4 Combination Insulins
5.2.4.8.5 Biosimilar Insulins
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 Basal or Long-acting Insulins
5.2.4.9.2 Bolus or Fast-acting Insulins
5.2.4.9.3 Traditional Human Insulins
5.2.4.9.4 Combination Insulins
5.2.4.9.5 Biosimilar Insulins
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 Basal or Long-acting Insulins
5.2.4.10.2 Bolus or Fast-acting Insulins
5.2.4.10.3 Traditional Human Insulins
5.2.4.10.4 Combination Insulins
5.2.4.10.5 Biosimilar Insulins
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 Basal or Long-acting Insulins
5.2.4.11.2 Bolus or Fast-acting Insulins
5.2.4.11.3 Traditional Human Insulins
5.2.4.11.4 Combination Insulins
5.2.4.11.5 Biosimilar Insulins
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 Basal or Long-acting Insulins
5.2.5.1.2 Bolus or Fast-acting Insulins
5.2.5.1.3 Traditional Human Insulins
5.2.5.1.4 Combination Insulins
5.2.5.1.5 Biosimilar Insulins
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 Basal or Long-acting Insulins
5.2.5.2.2 Bolus or Fast-acting Insulins
5.2.5.2.3 Traditional Human Insulins
5.2.5.2.4 Combination Insulins
5.2.5.2.5 Biosimilar Insulins
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 Basal or Long-acting Insulins
5.2.5.3.2 Bolus or Fast-acting Insulins
5.2.5.3.3 Traditional Human Insulins
5.2.5.3.4 Combination Insulins
5.2.5.3.5 Biosimilar Insulins
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 Basal or Long-acting Insulins
5.2.5.4.2 Bolus or Fast-acting Insulins
5.2.5.4.3 Traditional Human Insulins
5.2.5.4.4 Combination Insulins
5.2.5.4.5 Biosimilar Insulins
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 Basal or Long-acting Insulins
5.2.5.5.2 Bolus or Fast-acting Insulins
5.2.5.5.3 Traditional Human Insulins
5.2.5.5.4 Combination Insulins
5.2.5.5.5 Biosimilar Insulins
5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 Basal or Long-acting Insulins
5.2.5.6.2 Bolus or Fast-acting Insulins
5.2.5.6.3 Traditional Human Insulins
5.2.5.6.4 Combination Insulins
5.2.5.6.5 Biosimilar Insulins
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk AS
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Pfizer
7.1.6 Julphar
7.1.7 Exir
7.1.8 Sedico
7.1.9 Wockhardt
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Other Companies
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Lantus
Levemir
Toujeo
Tresiba
Basaglar
Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
NovoRapid/Novolog
Humalog
Apidra
Traditional Human Insulins (Value and Volume, 2012-2024)
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins (Value and Volume, 2012-2024)
NovoMix
Ryzodeg
Xultophy
Biosimilar Insulins (Value and Volume, 2012-2024)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Canada (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of North America (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Europe
France (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Germany (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Italy (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Spain (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
United Kingdom (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Russia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Europe (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Latin America
Mexico (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Brazil (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Latin America (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Asia-Pacific
Japan (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Korea (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
China (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
India (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Australia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Vietnam (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Malaysia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Indonesia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Philippines (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Thailand (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Asia-Pacific (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Iran (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Egypt (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Oman (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Africa (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Middle East & Africa (Value and Volume, 2012-2024)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Hemodynamic Monitoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The global hemodynamic monitoring market was valued at USD 249.06 million in 2018, and is estimated to be valued at USD 312.42 million in 2024, witnessing a CAGR of 3.85%. The key factors propelling the growth of this market are increase in the number of critically ill geriatric cases, rise in the prevalence of cardiac disorders and diabetes, increasing demand for home-based and non-invasive monitoring systems, advances in technology, due to funding by private players and government bodies, and increase in the number of people suffering from hypertension.
Scope of the Report
As per the scope of the report, critically ill patients require continuous monitoring of their vital parameters. This is done by direct pressure monitoring systems, which are also known as hemodynamic systems. The main function of these systems is to monitor the cardiac activity. The hemodynamic systems give information about blood pressure, blood volume, and fluid balance.
Key Market Trends
Minimally Invasive Monitoring Systems is Expected to hold its Highest Market Share in the System Segment
In the system segment of the market, minimally invasive monitoring systems are believed to have the largest market size and are expected to witness a CAGR of 8.0% during the forecast period.
The minimally invasive systems help in tracking stroke volume continuously and offer dynamic information of fluid responsiveness. Some of the systems provide the assessment of volumetric preload variables, while others highlight the continuous measurement of central venous saturation with proprietary catheters. These variables of minimally invasive systems, along with cardiac output, deliver improved hemodynamic monitoring.
There is a recent advancement in echocardiography device known as a transesophageal echocardiography device with a miniaturized probe, which is now used for continuous hemodynamic assessment. These monitoring systems have made hemodynamic calculations easier, which has gained the attention of healthcare providers, thus, resulting in the growth of the market.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for hemodynamic monitoring and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global hemodynamic monitoring market. The growth of the US hemodynamic monitoring market is the most notable, owing to the presence of major market players, technologically advanced hospitals, and an increasing number of critically ill patients being treated in hospitals of the region. In 2016, Cheetah Medical Inc. received FDA approval for Starling SV’, a non-invasive hemodynamic monitoring system.
With increasing FDA approvals for monitoring devices and new product launches, the US hemodynamic monitoring market is expected to grow during the forecast period.
Competitive Landscape
The hemodynamic monitoring market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new devices with fewer prices. Companies, like Getinge Group, Koninklijke Philips NV, Edwards Life Sciences Corporation, GE Healthcare, and LiDCO Group, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Critically Ill Geriatric Population
4.2.2 Rise in the Prevalence of Cardiac Disorders and Diabetes
4.2.3 Increasing Demand for Home-based and Non-invasive Monitoring Systems
4.2.4 Advances in Technology due to Funding by Private Players and Government Bodies
4.2.5 Increasing Number of People Suffering from Hypertension
4.3 Market Restraints
4.3.1 Increasing Incidences of Complications Associated with Invasive Monitoring Systems
4.3.2 Stringent FDA Guidelines for Approval of New Systems
4.3.3 Precision of CO Determinations Adversely Affected Under Low Flow Conditions
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By System
5.1.1 Minimally Invasive Monitoring Systems
5.1.2 Invasive Monitoring Systems
5.1.3 Non-invasive Monitoring Systems
5.2 By Application
5.2.1 Laboratory-based Monitoring Systems
5.2.2 Home-based Monitoring Systems
5.2.3 Hospital-based Monitoring Systems
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 LiDCO Group PLC
6.1.2 Cheetah Medical Inc.
6.1.3 ICU Medical Inc.
6.1.4 Tensys Medical Inc.
6.1.5 Schwarzer Cardiotek GmbH
6.1.6 Koninklijke Philips NV
6.1.7 Edwards Lifesciences Corporation
6.1.8 Getinge Group
6.1.9 GE Healthcare
6.1.10 Draeger Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By System
Minimally Invasive Monitoring Systems
Invasive Monitoring Systems
Non-invasive Monitoring Systems
By Application
Laboratory-based Monitoring Systems
Home-based Monitoring Systems
Hospital-based Monitoring Systems
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Hearing Aids Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global hearing aids market include the rising prevalence of hearing loss, technological advancements in hearing aids, the rise in global geriatric population and growing trend for customized implants.
With the increasing ageing population, there has been a rising prevalence of hearing loss. In the United States, hearing loss is more likely to be caused, owing to genetic defects. In developing countries, preventable medical issues are often the major factors for causing hearing loss, especially infections, such as rubella or syphilis, which can lead to congenital hearing loss. In addition, pregnancy complications also lead to hearing loss in infants. Thus, the increasing incidences of hearing disorders and hearing loss problems among the population have led to the sales of a large number of hearing devices in the market.
Growing noise pollution throughout the world has also a significant impact on the hearing abilities of people. Noise emission in heavy duty industries, as well as public carnivals, is expected to damage the hearing capacity of adults, thereby resulting in the increase in the demand for hearing aids devices.
There are various opportunities, like the incorporation of lithium-ion batteries in hearing aids, which help in propelling this market’s growth. Furthermore, technological developments related to the products that combine cochlear implants, and hearing aid technology to overcome the high-frequency hearing loss in patients, are also found creating new opportunities for the players in the global hearing aids market.
Scope of the Report
As per the scope of the report, hearing aids are sound amplifying devices that treat hearing impairment. These devices differ by design, technology used to achieve amplification, and special specific features. The market is expected to grow steadily with the increasing prevalence of hearing loss and increasing demand for technologically advanced products.
Key Market Trends
Behind the Ear (BTE) is the Segment by Product Type that is Expected to Grow the Fastest During the Forecast Period
The behind-the-ear hearing aid device segment held the largest market share, in terms of revenue, owing to better connectivity, high efficiency, and easy usage. It is also considered to be ideal for most of the people with hearing problems. BTE products, because of their wide range of applications and wider target patients, are expected to grow at a high rate over the forecast period.
The canal hearing aids segment is also likely to record a fast CAGR during the forecast time period, due to the growing demand for aesthetic and invisible appealing devices and the rising need for enhanced listening experience.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific region is expected to experience the fastest growth rate for hearing aid devices over the forecast period. There are factors, such as high noise pollution levels in countries, such as India, China, and Japan that have a major impact on the growth of this market. Other contributing factors are a large patient pool, an upsurge in the ageing population, and increasing healthcare infrastructure due to the involvement of private companies in research funding and services.
Competitive Landscape
The leading manufacturers of the global hearing aids market are focused on market consolidation and expansion of their product portfolio. Due to the increased number of benefits, companies are also found focusing on providing advanced hearing aid devices with lithium-ion batteries.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Hearing Loss
4.2.2 Technological Advancements in Hearing Aids
4.2.3 Rise in Global Geriatric Population
4.2.4 Increasing Trend for Customized Implants
4.3 Market Restraints
4.3.1 High Cost of Hearing Aids Devices
4.3.2 Social Stigmas
4.3.3 Presence of Product Substitutes
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Behind the Ear (BTE)
5.1.2 Receiver in the Ear (RITE)
5.1.3 In the Ear (ITE)
5.1.4 Canal Hearing Aids (CHA)
5.1.5 Other Hearing Aid Devices
5.2 By Type of Hearing Loss
5.2.1 Sensorineural Hearing Loss
5.2.2 Conductive Hearing Loss
5.3 By Technology
5.3.1 Conventional Hearing Aids
5.3.2 Digital Hearing Aids
5.4 By Patient Type
5.4.1 Adults
5.4.2 Pediatrics
5.5 By Distribution Channel
5.5.1 Wholesale Stores (Bigbox Stores)
5.5.2 Pharmacy Stores
5.5.3 E-commerce
5.5.4 Other Distribution Channels
5.6 Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East & Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East & Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amplifon
6.1.2 Audina Hearing Instruments Inc.
6.1.3 Cochlear Ltd
6.1.4 GN Hearing AS
6.1.5 Horentek
6.1.6 SeboTek Hearing Systems LLC
6.1.7 Siemens Healthcare GmBH
6.1.8 Sonova Holding AG
6.1.9 Starkey
6.1.10 Widex AS
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Behind the Ear (BTE)
Receiver in the Ear (RITE)
In the Ear (ITE)
Canal Hearing Aids (CHA)
Other Hearing Aid Devices
By Type of Hearing Loss
Sensorineural Hearing Loss
Conductive Hearing Loss
By Technology
Conventional Hearing Aids
Digital Hearing Aids
By Patient Type
Adults
Pediatrics
By Distribution Channel
Wholesale Stores (Bigbox Stores)
Pharmacy Stores
E-commerce
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Healthcare IT Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The global healthcare IT market was valued at USD 75,080.5 million in 2018, and is estimated to be valued at USD 15,0474.78 million in 2024, witnessing a CAGR of 12.29%. The rise in the demand for paperless technology, the emergence of social media and its impact on the healthcare IT industry are some of the major factors responsible for the current growth of the market studied. Along with these, increased funding from governments, various initiatives taken by the associations for the improvement of healthcare services and infrastructure, and a good return on investments are the other factors augmenting the growth of the market.
In today’s changing healthcare landscape, the usage of internet and social media has become important to develop a better understanding of healthcare information technologies and their impact on health communication. From 2005 to 2017, the participation in social networking sites had more than quadrupled and the adoption rate had gone high, which showed a positive impact on the growth of the market studied. According to CMS, the US National health expenditures represent approximately 18% of the GDP (Gross Domestic Product), which is expected to reach roughly 20%, by 2020. The majority of the growth is anticipated to be fuelled by public sector spending, specifically by Medicare and Medicaid. Medicaid and social security are expected to exceed government revenues. Thus, increasing investments in healthcare are likely to drive product innovation and technology acceptance, which, in turn, may propel the market studied, globally.
Scope of the Report
According to the United States Department of Health and Human Services, healthcare IT is defined as the application of information processing involving both computer hardware and software that deals with the storage, retrieval, sharing, and use of healthcare information, data, and knowledge for communication and decision-making. The main goal of the health information technology market is to maintain records containing the patients’ health information and delivering it to doctors, patients, or their families, in a safe and efficient way.
Key Market Trends
Services Sub-segment is Expected to hold its Highest Market Share in the Component Segment
In the component segment of the healthcare IT market, services are believed to have the largest market size and are expected to witness a CAGR of 12.77% during the forecast period.
The services sub-segment includes both support and maintenance and professional services. The services sub-segment held the largest market share in 2017 and is expected to grow significantly during the forecast period. Since the implementation of IT in healthcare, the amount of data has been increasing continuously; the storage and maintenance costs of data have increased over the last few years. Additionally, healthcare institutions lack skilled IT professionals to handle this huge amount of data. Hence, the increasing cost, along with lack of skilled professionals, has compelled several institutions to opt for the maintenance and support services provided by healthcare IT companies.
In addition to the maintaining and supporting services, analytics, which holds a significant market share, is also being provided by the leading players, such as IBM, GE Healthcare, Philips, etc. With the emergence and introduction of cloud-based technology in healthcare, the share of the services sub-segment has gone up significantly.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America, being the developed region, is currently dominating the market for healthcare IT and is expected to continue to hold the large market share for a few more years. The major factors responsible for the region’s largest market share in the future are the well-established healthcare industry and better reimbursement facilities in the region. The United States holds the majority of the market in the North American region; this is due to the higher adoption of digital healthcare in the country and the rising investments done by the companies over there.
Competitive Landscape
The healthcare IT market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new services at affordable prices. Companies, like GE Healthcare, Philips Healthcare, Siemens Healthcare, Cerner Corporation, and Allscripts Healthcare Solutions Inc., hold a substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Demand for Paper-less Technology
4.2.2 Emergence of Social Media and its Impact on the Healthcare IT Industry
4.2.3 Increased Government Funding on Healthcare Services and Infrastructure
4.2.4 Good Return of Investments (ROI)
4.3 Market Restraints
4.3.1 Lack of Skilled Labor
4.3.2 High Maintenance Costs
4.3.3 Reluctance to Shift to New Technology
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Business Segment
5.1.1 Hospital Information Systems (HIS)
5.1.2 Laboratory Information Systems (LIS)
5.1.3 Clinical Information Systems (CIS)
5.1.4 Radiology Information Systems (RIS)
5.1.5 Cardiovascular Information System (CVIS)
5.1.6 Electronic Health Records (EHR)
5.1.7 Telemedicine
5.1.8 Vendor Neutral Archive (VNA)
5.1.9 Picture Archiving and Communication System (PACS)
5.1.10 Clinical Decision Support System (CDSS)
5.1.11 Other Business Segments
5.2 By Component
5.2.1 Software
5.2.2 Hardware
5.2.3 Services
5.3 By Delivery Mode
5.3.1 On-premise
5.3.2 Cloud-based
5.4 By End User
5.4.1 Payers
5.4.2 Providers
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Philips Healthcare
6.1.3 Siemens Healthcare
6.1.4 Cerner Corporation
6.1.5 Allscripts Healthcare Solutions Inc.
6.1.6 Wipro
6.1.7 Oracle Corporation
6.1.8 IBM
6.1.9 SAS Institute Inc.
6.1.10 Dell Technologies Inc.
6.1.11 Mckesson Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Business Segment
Hospital Information Systems (HIS)
Laboratory Information Systems (LIS)
Clinical Information Systems (CIS)
Radiology Information Systems (RIS)
Cardiovascular Information System (CVIS)
Electronic Health Records (EHR)
Telemedicine
Vendor Neutral Archive (VNA)
Picture Archiving and Communication System (PACS)
Clinical Decision Support System (CDSS)
Other Business Segments
By Component
Software
Hardware
Services
By Delivery Mode
On-premise
Cloud-based
By End User
Payers
Providers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Healthcare IT Integration Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 119 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 119 pages
- Published: 07-06-2019
Market Overview
The global healthcare IT integration market was valued at USD 2,180.26 million in 2018, and is estimated to be valued at USD 3,973.32 million in 2024, witnessing a CAGR of 10.52%. The market is being driven by factors, such as the need to build a single platform for patients’ records and other healthcare providers, need to increase the efficiency of current medical practices and institutions, need to cut or contain healthcare expenditure, and rise in the demand for paperless technology.
The expenditure on health per capita in developed regions, such as North America and Europe, is already very high and is increasing rapidly in some regions. For instance, as per the report of CMS, the healthcare spending in the United States increased by 3.9% to reach USD 3.5 trillion, or USD 10,739 per person in 2017. Emerging economies, such as India, which already spend a lesser percentage of GDP on healthcare, are also looking for budget cut and one of the ways to go ahead is by introducing IT in healthcare. If these countries have to move toward less expenditure on healthcare, then they have to implement a more focused healthcare policy. For any policy to be implemented, comprehensive data is required about the past and present conditions and projection for the future, which is acutely missing in these countries.
In many of the instances, patients are asked to go for some tests and costs associated with them are really high. These tests may have been performed earlier by some other doctor at another lab, however, due to lack of a proper database for patient information, in most of the cases, patients have to go for the repetitive test. This is again adding to the overall healthcare cost. Use of IT in healthcare and integrating with other medical departments can minimize such repetitive tests by creating a comprehensive database for patients’ information, such as Electronic Medical Record (EMR). This indicates that there is a rising need to inculcate some modifications in the healthcare cost structure, which can be achieved by incorporating healthcare integration tools at the point of care.
Scope of the Report
Healthcare IT integration is defined as integrating information technology (IT) with operations in healthcare. The integration of information technology (IT) in healthcare includes a variety of automated methods that are used to manage information about people’s health and healthcare, for both individual and group of patients.
Key Market Trends
Interface Engines is Expected to hold the Highest Market Share in the Product Segment
In the product segment of the healthcare IT integration market, interface engines are believed to have the largest market size and are expected to witness a CAGR of 10.78% during the forecast period.
An interface engine, also known as an integration engine, is a software program that processes the data between various healthcare IT systems. These integration engines help IT departments tie together disparate systems, allowing the clinicians and other authorized users to access data housed within multiple EHRs or other applications. The role of an interface engine is to ease the workflow by providing flexibility to change direction and send alerts when any abnormal condition arises. Streamlined healthcare workflows and interface engines are a vital combination of support and delivery of the products. Some of the top interface engines found are Cloverleaf, Corepoint, Rhapsody, Datagate, and IGUANA. The interface engines are, thus, found to be less expensive and take less time to initially implement because an engine allows for the leveraging of data. An engine is flexible in its acceptance of data.
With the rising significance of the interface engine, there is a rapid future growth estimated for this segment.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for healthcare IT integration and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the well-established healthcare industry and better reimbursement facilities in the region. The United States holds the majority of the market in the North American region, due to the higher adoption of digital healthcare in the country and the rising investments done by the companies over there.
Competitive Landscape
The healthcare IT integration market is highly competitive and consists of several major players. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new ingredients with lesser prices. Companies, like Allscripts Healthcare Solutions Inc., Cerner Corporation, GE Healthcare, and IBM Corporation, hold a substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Need to Build a Single Platform for Patient’s Record and Other Healthcare Providers
4.2.2 Need to Increase Efficiency of Current Medical Practices and Institution
4.2.3 Need to Cut or Contain Healthcare Expenditure
4.2.4 Rise in the Demand for Paperless Technology
4.3 Market Restraints
4.3.1 Lack of Skilled Professionals in Healthcare
4.3.2 High Maintenance and Security Cost
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Interface Engines
5.1.2 Medical Device Integration Setup
5.1.3 Other Products
5.2 By Mode of Service
5.2.1 Operation Services
5.2.2 Support and Upkeep Services
5.2.3 Training
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Labs
5.3.4 Radiology
5.3.5 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 Cerner Corporation
6.1.3 GE Healthcare
6.1.4 IBM Corporation
6.1.5 Siemens Healthcare GmbH
6.1.6 Corepoint Health LLC
6.1.7 InterSystems Corporation
6.1.8 Oracle Corporation
6.1.9 Orion Health
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Interface Engines
Medical Device Integration Setup
Other Products
By Mode of Service
Operation Services
Support and Upkeep Services
Training
By End User
Hospitals
Clinics
Labs
Radiology
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America